Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-02

Shattuck Labs (STTK)

CEO Taylor Schreiber was paid $1,532,763 in fiscal year 2025, ↓ down 52.3% from fiscal year 2024, the 25th percentile of its disclosed peer group (SEC filing 0001193125-26-146293 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$1,532,763 ↓
Taylor Schreiber total, FY2025
25th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
91.96%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

STTK's next annual pay disclosure, estimated February 24, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Taylor Schreiber$565,600$0$0$656,531$296,940$0$13,692$1,532,763
Chief Executive Officer
Arunthathy Nirmalini (Lini) Pandite502,98000197,746211,252020,667932,645
Chief Medical Officer
Andrew Neill467,16000205,226196,207014,840883,433
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Taylor Schreiber$1,532,763$3,216,407$1,034,408↓ −1,683,644
Arunthathy Nirmalini (Lini) Pandite932,645———
Andrew Neill883,4332,052,586911,757↓ −1,169,153

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Shattuck Labs's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper STTK reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against STTK

The list of companies that name STTK as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Andrew NeillCFO$883,433
Arunthathy Nirmalini (Lini) PanditeChief Medical Officer$932,645
Taylor SchreiberCEO$1,532,763
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Carrie BrownsteinFormer director (through FY2025)$51,510
Clay SiegallIndependent Director$68,844
Daniel BakerIndependent Director$72,528
George GolumbeskiIndependent Director$99,677
Helen M. BoudreauIndependent Director$77,177
Kate SasserFormer director (through FY2025)$51,510
Michael LeeFormer director (through FY2025)$48,844
Mona AshiyaIndependent Director$68,694
Neil GibsonIndependent Director$77,677
Tyler BrousFormer director (through FY2025)$60,510
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Andrew NeillOption214,0001.18—
Arunthathy Nirmalini (Lini) PanditeOption206,2001.18—
Arunthathy Nirmalini (Lini) PanditeRSU8,684—31,697
Andrew NeillRSU8,331—30,408
Arunthathy Nirmalini (Lini) PanditeOption1,4477.43—
Andrew NeillRSU42,375—154,669
Arunthathy Nirmalini (Lini) PanditeRSU34,856—127,224
Taylor SchreiberOption171,9289.41—
Arunthathy Nirmalini (Lini) PanditeRSU18,937—69,120
Andrew NeillRSU17,462—63,736
Taylor SchreiberOption684,6001.18—
Arunthathy Nirmalini (Lini) PanditeOption18,8923.57—
Arunthathy Nirmalini (Lini) PanditeOption48,41210.09—
Andrew NeillOption1,3897.43—
Andrew NeillOption18,9183.57—
Andrew NeillOption58,85510.09—
05

Incentive-plan design — the Compensation Discussion & Analysis

The objectives of the Compensation Committee’s compensation philosophy are to attract, retain, and motivate superior executive talent through providing incentives that reward the achievement of performance goals correlated to enhancing shareholder value and aligning the executive’s interests with those of shareholders through long-term incentives linked to specific performance.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedging—
Anti-pledging—
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-2849,849,8874,356,1991,66091.96%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2891.96%a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
George GolumbeskiIndependent · Compensation Committee$77,500—$22,177——$99,677
Neil GibsonIndependent · Audit Committee · Nominating and Corporate Governance Committee (Chair)55,500—22,177——77,677
Helen M. BoudreauIndependent · Audit Committee (Chair)55,000—22,177——77,177
Daniel BakerIndependent · Audit Committee · Newly elected17,167—55,361——72,528
Clay SiegallIndependent · Compensation Committee (Chair)46,667—22,177——68,844
Mona AshiyaIndependent · Nominating and Corporate Governance Committee · Newly elected13,333—55,361——68,694
Tyler BrousIndependent · Departed during FY38,333—22,177——60,510
Carrie BrownsteinIndependent · Departed during FY29,333—22,177——51,510
Kate SasserIndependent · Departed during FY29,333—22,177——51,510
Michael LeeIndependent · Departed during FY26,667—22,177——48,844
Taylor SchreiberEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)7,500 / 10,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$388,833
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$388,833

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Shattuck Labs names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Shattuck Labs.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Iteos Therapeutics2024Michel Detheux$628,684$0$4,965,264$421,014$6,085,657
2ORIC Pharmaceuticals2025Jacob Chacko657,500826,0003,634,560434,0005,567,164
3Precigen2025Helen Sabzevari1,000,0002,215,0001,069,2001,049,9975,354,329
4CytomX Therapeutics2025Sean McCarthy675,2901,150,4632,158,170749,5724,738,495
5IGM Biosciences2023Fred Schwarzer646,797868,0501,336,743355,7383,207,328
6ALX Oncology2025Jason Lettmann724,50001,447,488298,8562,470,844
7Black Diamond Therapeutics2025Mark Velleca667,400189,0001,006,030348,7172,234,919
8Precision BioSciences2025Michael Amoroso650,8751,025,086002,189,467
9PMV Pharmaceuticals2025David Mack628,4610752,320284,4101,665,191
10Mersana Therapeutics2024Michael Huber632,500133,635518,044322,5751,613,754
11Shattuck Labs2025Taylor Schreiber565,6000656,531296,9401,532,763
12Prelude Therapeutics2025Krishna Vaddi615,4410412,744309,4651,348,000
13Kezar Life Sciences2024Christopher Kirk600,00000313,500927,300
14Century Therapeutics2025Gregory Russotti559,65071,12051,240226,658912,320
—HOOKIPA Pharma——————not in coverage universe
—Gritstone bio——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Shattuck Labsnot disclosedOption 100not disclosedAon
ALX Oncologynot disclosednot disclosednot disclosedCompensia
Black Diamond Therapeutics95%not disclosednot disclosedAon Human Capital Solutions (Aon plc)
Century Therapeuticsnot disclosednot disclosednot disclosednot disclosed
CytomX Therapeuticsnot disclosednot disclosednot disclosedAon
Gritstone bionot disclosednot disclosednot disclosednot disclosed
HOOKIPA Pharmanot disclosednot disclosednot disclosednot disclosed
IGM Biosciencesnot disclosednot disclosednot disclosedAon
Iteos Therapeuticsnot disclosednot disclosednot disclosedRadford
Kezar Life Sciencesnot disclosednot disclosednot disclosednot disclosed
Mersana Therapeuticsnot disclosedOption 75 · RSU 25not disclosedPearl Meyer & Partners, LLC
ORIC Pharmaceuticalsnot disclosednot disclosednot disclosedAon
PMV Pharmaceuticalsnot disclosedOption 100not disclosedPearl Meyer & Partners, LLC
Precigen140%not disclosednot disclosedAon
Precision BioSciences115%RSU 100not disclosedAon
Prelude Therapeuticsnot disclosedOption 100not disclosedCompensia

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Shattuck Labs in fiscal 2025?
As disclosed, Taylor Schreiber (Chief Executive Officer) was the highest-paid executive at Shattuck Labs in fiscal 2025, with total compensation of $1,532,763.
How does Shattuck Labs's chief executive pay compare to its disclosed peer group?
As disclosed, Taylor Schreiber's total compensation ranked at the 25th percentile of Shattuck Labs's disclosed peer group.
How did shareholders vote on Shattuck Labs's executive compensation?
As disclosed, 91.96% of shareholders supported Shattuck Labs's executive compensation in the latest say-on-pay vote.
How much does Shattuck Labs spend in total on board compensation for fiscal 2025?
As disclosed, Shattuck Labs reported total board compensation of $388,833 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Taylor SchreiberDEF 14A2026-04-080001193125-26-146293Section “Executive Compensation”. As printed: 1,532,763. Filing ↗machine: r2 · c27 · span 274803–274812
2Section 01, Arunthathy Nirmalini (Lini) PanditeDEF 14A2026-04-080001193125-26-146293Section “Executive Compensation”. As printed: 932,645. Filing ↗machine: r4 · c27 · span 279148–279155
3Section 01, Andrew NeillDEF 14A2026-04-080001193125-26-146293Section “Executive Compensation”. As printed: 883,433. Filing ↗machine: r6 · c27 · span 283449–283456
4Section 08, George GolumbeskiDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 99,677. Filing ↗machine: span 236943–236949
5Section 08, Neil GibsonDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 77,677. Filing ↗machine: span 236216–236222
6Section 08, Helen M. BoudreauDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 77,177. Filing ↗machine: span 234013–234019
7Section 08, Daniel BakerDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 72,528. Filing ↗machine: span 233303–233309
8Section 08, Clay SiegallDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 68,844. Filing ↗machine: span 239135–239141
9Section 08, Mona AshiyaDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 68,694. Filing ↗machine: span 232561–232567
10Section 08, Tyler BrousDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 60,510. Filing ↗machine: span 234748–234754
11Section 08, Carrie BrownsteinDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 51,510. Filing ↗machine: span 235530–235536
12Section 08, Kate SasserDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 51,510. Filing ↗machine: span 238448–238454
13Section 08, Michael LeeDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 48,844. Filing ↗machine: span 237681–237687
14Section 08, Taylor SchreiberDEF 14A2026-04-080001193125-26-146293Section “Director Compensation”. As printed: 0. Filing ↗
15Section 06, 2026 voteForm 8-K2026-06-020001193125-26-253784Item 5.07 · say-on-pay result. As reported: 91.96% (votes for as printed: 49,849,887). Filing ↗
16Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
17Section 09b board cost (computed)Computed——Cash 388,833 + equity 0 + all other 0 = 388,833, summed across the director compensation table rows.machine: formula: Σ = 388,833
18Iteos Therapeutics, Section 10b CEO totalDEF 14A2025-04-240000950170-25-057666CEO total compensation as printed in Iteos Therapeutics's own proxy. As printed: 6,085,657. Filing ↗machine: r2 · c27 · span 499272–499281
19ORIC Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-280001193125-26-186911CEO total compensation as printed in ORIC Pharmaceuticals's own proxy. As printed: 5,567,164. Filing ↗machine: r2 · c26 · span 435191–435200
20Precigen, Section 10b CEO totalDEF 14A2026-04-300001140361-26-018214CEO total compensation as printed in Precigen's own proxy. As printed: 5,354,329. Filing ↗machine: r2 · c24 · span 721439–721448
21CytomX Therapeutics, Section 10b CEO totalDEF 14A2026-04-300001140361-26-018237CEO total compensation as printed in CytomX Therapeutics's own proxy. As printed: 4,738,495. Filing ↗machine: r2 · c24 · span 739353–739362
22IGM Biosciences, Section 10b CEO totalDEF 14A2024-04-260000950170-24-049091CEO total compensation as printed in IGM Biosciences's own proxy. As printed: 3,207,328. Filing ↗machine: r2 · c21 · span 824822–824831
23ALX Oncology, Section 10b CEO totalDEF 14A2026-04-200001193125-26-163936CEO total compensation as printed in ALX Oncology's own proxy. As printed: 2,470,844. Filing ↗machine: r2 · c29 · span 706901–706910
24Black Diamond Therapeutics, Section 10b CEO totalDEF 14A2026-04-290001104659-26-051474CEO total compensation as printed in Black Diamond Therapeutics's own proxy. As printed: 2,234,919. Filing ↗machine: r1 · c41 · span 370031–370040
25Precision BioSciences, Section 10b CEO totalDEF 14A2026-04-080001140361-26-013757CEO total compensation as printed in Precision BioSciences's own proxy. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005
26PMV Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-220001140361-26-016038CEO total compensation as printed in PMV Pharmaceuticals's own proxy. As printed: 1,665,191. Filing ↗machine: r2 · c27 · span 469868–469877
27Mersana Therapeutics, Section 10b CEO totalDEF 14A2025-04-290001104659-25-040448CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. Filing ↗machine: r1 · c41 · span 608188–608197
28Shattuck Labs (subject), Section 10b CEO totalDEF 14A2026-04-080001193125-26-146293CEO total compensation as printed in Shattuck Labs's own proxy. As printed: 1,532,763. Filing ↗machine: r2 · c27 · span 274803–274812
29Prelude Therapeutics, Section 10b CEO totalDEF 14A2026-04-290001193125-26-191532CEO total compensation as printed in Prelude Therapeutics's own proxy. As printed: 1,348,000. Filing ↗machine: span 557496–557505
30Kezar Life Sciences, Section 10b CEO totalDEF 14A2025-04-250001645666-25-000020CEO total compensation as printed in Kezar Life Sciences's own proxy. As printed: 927,300. Filing ↗machine: span 286147–286154
31Century Therapeutics, Section 10b CEO totalDEF 14A2026-04-270001104659-26-049489CEO total compensation as printed in Century Therapeutics's own proxy. As printed: 912,320. Filing ↗machine: r3 · c26 · span 521444–521451
32Section 10a, Precigen reciprocityDEF 14A—0001140361-26-018214Precigen's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗
33Section 10a, IGM Biosciences reciprocityDEF 14A—0000950170-24-049091IGM Biosciences's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗
34Section 10a, Precision BioSciences reciprocityDEF 14A—0001140361-26-013757Precision BioSciences's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗
35Section 10a, Mersana Therapeutics reciprocityDEF 14A—0001104659-25-040448Mersana Therapeutics's most recent proxy was read; its disclosed peer group does not include Shattuck Labs. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.